openPR Logo
Press release

Biosimilars Market Report, Size, Share, Insights 2024-2031 - Amgen Inc, Novartis AG & Pfizer Inc.

09-06-2024 03:05 PM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Biosimilars Market || 2024-2031

Biosimilars Market || 2024-2031

The global biosimilars market, valued at USD 30.1 billion in 2022, is poised for significant expansion, with projections estimating it will reach USD 76.7 billion by 2031. This growth represents a robust CAGR of 12.8% from 2024 to 2031.

Biosimilars are biological products designed to be highly similar to already approved reference biologics, demonstrating no significant clinical differences in terms of efficacy, safety, and quality. They are used to treat a range of conditions across various therapeutic areas, including rheumatology, oncology, hematology, gastroenterology, and endocrinology.

Get a Free Sample Research PDF - https://www.datamintelligence.com/download-sample/biosimilars-market

Market Trends:

The rising number of biosimilar drug approvals by the FDA drives global biosimilar market growth.

The global biosimilars market is anticipated to grow significantly, driven by the increase in approved biosimilars due to enhanced FDA review processes and advancements in manufacturing and development techniques. For instance, in March 2022, Amneal Pharmaceuticals, Inc. received FDA approval for filgrastim-ayow, a biosimilar to Neupogen, which will be marketed under the RELEUKO brand. This approval reflects the growing familiarity of manufacturers with the complex regulatory and legal frameworks for biosimilars, leading to a rise in biosimilar submissions.

However, the development of biosimilars is hampered by high costs and long timelines. Producing a biosimilar can take 7 to 8 years and cost between $100 million and $300 million, which poses a significant barrier to market growth, particularly in lower-income regions. The substantial research and development expenses contribute to the slow acceptance and proliferation of biosimilars, affecting overall market expansion.

Market Segmentation:

By Product: Monoclonal Antibodies,Recombinant Human Growth Hormone (rhGH), Insulin, Anti-coagulants, Erythropoietin, Fusion Proteins, Granulocyte Colony Stimulating Factor, Follitropin.

By Technology: Recombinant DNA Technology (rDNA technology), Monoclonal Antibodies (MAb) Technology.

By Application: Oncology, Chronic and Immune Diseases, Infectious Diseases, Growth Hormone Deficiency, Blood Disorders.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biosimilars-market

Competitive Landscape:

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Pfizer Inc.
• Biocon
• Samsung Bioepis
• Mylan NV
• Celltrion
• Biogen
• Intas Pharmaceutical Ltd

Regional Analysis:

The Biosimilars Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Biosimilars Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Key Developments:

In May 2023, Gulf Pharmaceutical Industries PJSC (Julphar), a major pharmaceutical producer in the Middle East and Africa, announced a strategic licensing agreement with Sunshine Lake Pharma, a Chinese pharmaceutical company. This partnership will position Julphar as the first manufacturer of modern insulin biosimilars in the MENA region, marking a significant milestone in the regional pharmaceutical industry.

Related Reports:

Occupational Medicines Market: https://datamintelligence.com/research-report/occupational-medicines-market

Collagen and Gelatin Market: https://datamintelligence.com/research-report/collagen-and-gelatin-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market Report, Size, Share, Insights 2024-2031 - Amgen Inc, Novartis AG & Pfizer Inc. here

News-ID: 3648121 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Exocrine Pancreatic Insufficiency Treatment Market 2024-2031: Comprehensive Analysis of Pancreatic Enzyme Replacement Therapy, Nutritional Management, Emerging Therapies, and Strategic Growth Opportunities
United States Exocrine Pancreatic Insufficiency Treatment Market 2024-2031: Comp …
The Global Exocrine Pancreatic Insufficiency Treatment Market reached US$ 3.30 billion in 2023 and is expected to reach US$ 5.37 billion by 2031, growing at a CAGR of 6.4% during the forecast period 2024-2031. Exocrine Pancreatic Insufficiency (EPI) is a condition where the pancreas fails to produce sufficient digestive enzymes, leading to malabsorption, nutrient deficiencies, and gastrointestinal issues. Treatments primarily involve pancreatic enzyme replacement therapy (PERT), dietary modifications, and adjunctive nutritional
Herpes Labialis Drugs Market 2024-2031: Comprehensive Analysis of Antiviral Therapeutics, Topical and Oral Formulations, Emerging Therapies, and Strategic Market Opportunities | GlaxoSmithKline Pharmaceuticals, Bauch Health Inc., Novartis AG
Herpes Labialis Drugs Market 2024-2031: Comprehensive Analysis of Antiviral Ther …
The global herpes labialis drugs market reached US$ 1.16 billion in 2023 and is expected to reach US$ 1.7 billion by 2031 growing with a CAGR of 4.8% during the forecast period 2024-2031. Herpes labialis, commonly known as cold sores, is caused by the Herpes Simplex Virus-1 (HSV-1). Treatment options include antiviral drugs such as acyclovir, valacyclovir, famciclovir, and topical formulations, which help reduce symptoms, accelerate healing, and prevent recurrence. The
United States Chronic Inflammatory Demyelinating Polyneuropathy Market 2024-2031: In-Depth Analysis of Immunoglobulin Therapy, Corticosteroids, Plasma Exchange, and Emerging Biologics | Top Companies are Grifols, Baxter, Kedrion S.p.A
United States Chronic Inflammatory Demyelinating Polyneuropathy Market 2024-2031 …
Chronic Inflammatory Demyelinating Polyneuropathy Market is valued at a significant CAGR during the forecast period (2024-2031). Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder that leads to progressive weakness, numbness, and sensory impairment in the limbs. Current treatments include corticosteroids, intravenous immunoglobulin (IVIg), plasma exchange (plasmapheresis), and emerging biologics. The market is expanding due to increasing disease awareness, advances in therapeutic options, early diagnosis, and growing adoption of patient-centric
United States Varicella Zoster Infections Treatment Market 2024-2031: In-Depth Analysis of Antivirals, Vaccines, Pain Management Therapies, and Emerging Therapeutic Innovations | Bausch Health Companies Inc., LNHC, Inc., GSK plc.
United States Varicella Zoster Infections Treatment Market 2024-2031: In-Depth A …
Global Varicella Zoster Infections Treatment Market reached US$ 1,799.42 million in 2023 and is expected to reach US$ 2,523.90 million by 2031, growing at a CAGR of 4.3% during the forecast period 2024-2031. Varicella Zoster Virus (HHV-3) causes chickenpox (varicella) and shingles (herpes zoster). Treatments include antiviral drugs (acyclovir, valacyclovir, famciclovir), vaccines, and pain management therapies to prevent complications and manage symptoms. The market is growing due to increasing prevalence of

All 5 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the